10 November 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice on nine medicines.

Durvalumab (Imfinzi) was accepted, when used together with tremelimumab, as a first-line treatment for adults with advanced hepatocellular carcinoma, the most common type of liver cancer.

Read SMC press release